Latest News
- September 12, 2025Join CBCC at CPHI Frankfurt 2025
- August 08, 2025International Publication of Phase II clinical Trial
- August 06, 2025Experience Agility-driven clinical trials with CBCC!
- July 23, 2025Discover the drive for swiftness in clinical research!
- July 16, 2025ANDA Approval Doxorubicin Hydrochloride Liposome
May 28, 2024
IND application submitted by CBCC
We are excited to announce that we have reached a significant milestone!
IND application submitted by CBCC, acting as a US agent for a Biotech company, was accepted by USFDA and applicant has received ‘STUDY MAY PROCEED’ letter!
Type of application: 505(b)(1)
Therapeutic Area: Oncology
Scope: End-to-end regulatory services.
We are now gearing up for the FIH trial in the US!
CBCC Global Research: CHANGING LIVES THROUGH HOPE AND INNOVATION